Pancreatic Cancer: Genomics, Therapy and Survival
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 July 2026 | Viewed by 4
Special Issue Editor
2. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Interests: oncolytic viral therapy; cancer vaccine; pancreatic cancer; biliary tract cancer
Special Issue Information
Dear Colleagues,
Pancreatic cancer is the 12th most common cancer in the world, and with its high mortality rate it is ranked as the 7th leading cause of cancer deaths. Gemcitabine is well known as a first-line chemotherapy for stage III and stage IV pancreatic cancer. Gemcitabine has been considered the standard of care for the treatment of advanced pancreatic cancer since 1997. Multiple clinical trials have been attempted to improve outcomes by using gemcitabine as a backbone chemotherapy. However, since it still has a poor prognosis, additional new therapy would need to be developed. CAF causes resistance against anticancer therapy. The currently available chemotherapy for pancreatic cancer is not very effective, so the development of new treatments is expected. Oncolytic virotherapy is a promising new strategy to treat most human cancers. Some oncolytic viruses for pancreatic cancer have already been reported. RNA viruses are likely to be a safer method, which replicate in the host cytosol without the DNA phase. Therefore, they do not have the gene toxicity caused by the integration of the viral genome into the host DNA. In particular, the enteroviruses, which are members of the Picornaviridae family in a group of RNA viruses, might be promising candidates for oncolytic virotherapy. Here, we focus on comprehensive research articles or reviews that include more emerging therapies for pancreatic cancer and improved prognoses, including oncolytic viruses.
Dr. Hisanobu Ogata
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreas
- cancer
- treatment
- oncolytic virus
- stromal cell
- cancer-associated fibroblast (CAF)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
